Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
May 17 2021 - 9:00AM
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision
oncology company developing next-generation therapies that target
genetic drivers of cancer, today announced the appointment of Kumar
Srinivasan, Ph.D., MBA, as executive vice president and chief
business officer, effective June 1. Dr. Srinivasan has over 20
years of experience in pharmaceutical and biotechnology companies,
most recently as vice president and global head of business
development for the BioPharmaceutical business unit of AstraZeneca.
“As we advance now four clinical stage drug candidates and
enhance our pipeline for the future, Kumar brings deep expertise to
help guide our corporate strategy and business development
priorities,” said Athena Countouriotis, M.D., president and CEO.
“We look forward to having Kumar join our growing team.”
Dr. Srinivasan will be responsible for corporate strategy and
business development, including collaborations and alliances.
During his 9-year tenure at AstraZeneca, Dr. Srinivasan was
responsible for all in- and out-licensing, business development and
alliance management activities within several therapeutic areas on
a regional and global scale. In addition, he previously held
executive level business development roles at Wyeth; Vivoryon
(formerly known as Probiodrug), a publicly traded biotech based in
Germany; and Torrey Pines Therapeutics. Earlier in his career, he
held scientific roles at biopharmaceutical companies, Sibia
Neurosciences and Genta. Dr. Srinivasan earned his MBA from the
University of Chicago’s Booth School of Business, his Ph.D. in
organic chemistry from Case Western Reserve University and did his
postdoctoral research at Caltech under Professor Frances
Arnold.
“The depth of the Turning Point clinical pipeline combined with
its innovative discovery programs provide an exciting platform to
continue to grow the company,” said Dr. Srinivasan. “I am impressed
by the entire Turning Point team, and look forward to working with
the company to advance its vision to be the leader in precision
oncology.”
About Turning Point Therapeutics Inc.Turning
Point Therapeutics is a clinical-stage precision oncology
company with a pipeline of internally discovered investigational
drugs designed to address key limitations of existing cancer
therapies. The company’s lead drug candidate, repotrectinib, is a
next-generation kinase inhibitor targeting the ROS1 and TRK
oncogenic drivers of non-small cell lung cancer and advanced solid
tumors. Repotrectinib, which is being studied in a registrational
Phase 2 study in adults and a Phase 1/2 study in pediatric
patients, has shown antitumor activity and durable responses among
kinase inhibitor treatment-naïve and pre-treated patients. The
company’s pipeline of drug candidates also includes TPX-0022,
targeting MET, CSF1R and SRC, which is being studied in a Phase 1
trial of patients with advanced or metastatic solid tumors
harboring genetic alterations in MET; TPX-0046, targeting RET,
which is being studied in a Phase 1/2 trial of patients with
advanced or metastatic solid tumors harboring genetic alterations
in RET; and TPX-0131, a next-generation ALK inhibitor, which is
being studied in a Phase 1/2 trial of previously treated patients
with ALK-positive advanced or metastatic non-small cell lung
cancer. Turning Point’s next-generation kinase inhibitors are
designed to bind to their targets with greater precision and
affinity than existing therapies, with a novel, compact structure
that has demonstrated an ability to potentially overcome treatment
resistance common with other kinase inhibitors. The company is
driven to develop therapies that mark a turning point for patients
in their cancer treatment. For more information, visit
www.tptherapeutics.com.
Forward Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “plans”, “will”,
“believes,” “anticipates,” “expects,” “intends,” “goal,”
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
based upon Turning Point Therapeutics’ current expectations and
involve assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Turning Point Therapeutics’
business in general, risks and uncertainties related to the impact
of the COVID-19 pandemic to Turning Point’s business and the other
risks described in Turning Point Therapeutics’ filings with the
SEC. All forward-looking statements contained in this press release
speak only as of the date on which they were made. Turning Point
Therapeutics undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
Contact: Jim
Mazzolajim.mazzola@tptherapeutics.com858-342-8272
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Turning Point Therapeutics (NASDAQ:TPTX)
Historical Stock Chart
From Sep 2023 to Sep 2024